The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer

Expert Opinion on Biological Therapy

Volumn 12, Issue 2, 2012, Pages 259-263

  Keir, Christopher H ^a   Vahdat, Linda T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Breast cancer; CDX 011; Glembatumumab vedotin; GPNMB; Monoclonal antibody; Osteoactivin

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; EPOTHILONE A; GEMCITABINE; GLEMBATUMUMAB VEDOTIN; GLYCOPROTEIN; GLYCOPROTEIN NBM; LAPATINIB; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER PATIENT; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HUMAN; HYPOKALEMIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOCONJUGATES; TREATMENT OUTCOME;

EID: 84855702068     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.642357     Document Type: Article

References (18)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;12:277-300
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
3. Muller V, Witzel I, Stickeler E. Immunological approaches in the treatment of metastasized breast cancer. Breast Care 2009;4 (6):359-66
4. Govindan S, Goldenberg D. New antibody conjugates in cancer therapy. Sci World J 2010;10:2070-89
5. Investigator's brochure for CR011-vcMMAE. CuraGen Corp., version 2, March 18, 2008
6. Tse K, Jeffers M, Pollack V, et al. CRO11, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Caner Res 2006;12 (4):1373-82 (Pubitemid 43342531)
7. Rich J, Shi Q, Hjelmeland M, et al. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 2003;278 (18):15951-7 (Pubitemid 36799713)
8. Onaga M, Ido A, Hasuike S, et al. Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells. J Hepatol 2003;39 (5):779-85 (Pubitemid 37372188)
9. Rose AA, Pepin F, Russo C, et al. Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 2007;5 (10):1001-14 (Pubitemid 350070756)
10. Rose A, Grosset A, Dong Z, et al. Glycoprotein Nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 2010;16:2147-56
11. Pollack V, Alvarez E, Tse E, et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011- vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol 2007;60 (3):423-35 (Pubitemid 46944592)
12. Rose A, Dong Z, MacDonald P, et al. GPNMB is Novel Pro-Angiogenic Factor and Therapeutic Target in Breast Cancer. Poster Presented at MISAM (Montreal International Symposium on Angiogenesis and Metastasis 2009
13. Kovtun Y, Audette C, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006;66 (6):3214-21
14. Burris H, Saleh M, Bendell J, et al. A Phase I/II Study of CR011-vcMMAE (CDX-011), an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer [abstract 6096]. 2009 San Antonio Breast Cancer Symposium (SABCS
15. Hwu P, Sznol M, Pavlick A, et al. A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma. J Clin Oncol 2009;27 (15 Suppl):abstract 9032
16. Saleh M, Bendell J, Rose R, et al. Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with antibody-drug conjugate (ADC), CDX-011 (CR011-vMMAE). J Clin Oncol 2010;28 (15 Suppl):abstract 1095
17. Barry D, Cronin K, Plevritis S, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. NEJM 2005;353:1784-92 (Pubitemid 41549890)
18. Alley S, Okeley N, Senter P. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14 (4):529-37